Everist Genomics (Ann Arbor, Michigan), a prognostics company focused on developing gene-based molecular assays for the prediction of cancer recurrence, reported the positive results of the first external validation study of its OncoDefender-CRC colorectal cancer recurrence test. The study is being conducted by Mayo Validation Support Services, an affiliate of the Mayo Clinic (Rochester, Minnesota) and is being coordinated with investigators and resources from all three Mayo Clinic sites. (Medical Device Daily)
Read More
